Research study for adults with relapsing-remitting MS


A Randomized Controlled Trial of Vitamin D in Multiple Sclerosis


Jones David, E

UVa Health System, Department of Neurology seeks men and women age 18 to 50 years with relapsing-remitting Multiple Sclerosis for research study. The purpose of the study is to determine whether vitamin D3 supplementation as an add-on to Copaxone therapy will affect the relapse rate of MS. Study involves taking Copaxone by injection, as well as one of 2 doses of vitamin D. There are blood draws, surveys, neurological evaluations, urine pregnancy testing (for females of child-bearing potential), and MRI of the brain. There are 11 visits over 26 months, adding up to 2 hours to regular clinical visits for 6 visits, a 2 hour injection training visit, and the other visits lasting approximately 45 minutes. Eligible participants have had at least 1 recent relapse of their MS. ? Participant’s insurance company will be billed for clinic visits, MRIs, labs (after the screening labs) ? Study medication—Copaxone and vitamin D—are provided free of charge, as are 4 clinic visits with the research coordinator, and the screening labs ? No compensation is provided for this study. Contact Information: For more information please contact: • Margaret Keller RN • 434-243-5457 or • IRB-HSR # 16493 Principal Investigator: David E. Jones MD


Multiple Sclerosis



No Compensation

Margaret Keller